Drug – bio-affecting and body treating compositions – In vivo diagnosis or in vivo testing – Ultrasound contrast agent
Patent
1995-05-30
1997-12-09
Hollinden, Gary E.
Drug, bio-affecting and body treating compositions
In vivo diagnosis or in vivo testing
Ultrasound contrast agent
12866202, A61B 813
Patent
active
056957408
ABSTRACT:
The invention relates to a new ultrasound contrast agent of the type which relies on microbubbles for echogenicity. The new contrast agent comprises microbubbles with an internal atmosphere enhanced with a perfluorocarbon gas which is effective for visually detecting myocardial uptake upon echocardiogram following peripheral intravenous injection of said agent into a host. The contrast agent of this invention is unique in that it makes possible the non-invasive visual detection of myocardial uptake. In addition, the contrast agent of this invention makes feasible safe and consistent, non-invasive methods for visually assessing, qualitatively or quantitatively, not only myocardial perfusion, but renal and hepatic perfusion, and for detecting severity of coronary arterial stenosis.
REFERENCES:
patent: 4572203 (1986-02-01), Feinstein
patent: 4718433 (1988-01-01), Feinstein
patent: 4774958 (1988-10-01), Feinstein
patent: 4844882 (1989-07-01), Widder et al.
patent: 4957656 (1990-09-01), Cerny et al.
patent: 5107842 (1992-04-01), Levene et al.
patent: 5304325 (1994-04-01), Kaufman et al.
patent: 5315997 (1994-05-01), Widder et al.
patent: 5380519 (1995-01-01), Schneider et al.
patent: 5385147 (1995-01-01), Anderson et al.
patent: 5385725 (1995-01-01), Lin et al.
patent: 5393524 (1995-02-01), Quay
patent: 5401493 (1995-03-01), Lohrmann et al.
patent: 5409688 (1995-04-01), Quay
patent: 5413774 (1995-05-01), Schneider et al.
patent: 5445813 (1995-08-01), Schneider et al.
patent: 5512268 (1996-04-01), Grinstaff et al.
patent: 5540909 (1996-07-01), Schutt
patent: 5542935 (1996-08-01), Unger et al.
patent: 5552133 (1996-09-01), Lambert et al.
patent: 5558853 (1996-09-01), Quay
Kricsfeld et al, "Detection of Regional Perfusion Abnormalities During Adenosine Stress Echocardiography Using Intravenous Perfluoropropane-Enhanced Sonicated Dextrose Albumin", Abstract No. 703-2, 44th Annual Scientific Session of the American College of Cardiology, New Orleans, LA, USA, Mar. 19-22, 1995. In: Journal of the American College of Cardiology, Spec. Issue, p. 38A, XP000577057.
Porter, et al, "Multifold Sonicated Dilutions of Albumin with Fifty Percent Dextrose Improve Left Ventricular Contrast Videonintensity After Intravenous Injection in Human Beings", abstract, J. Am Soc. Echocardiogr, Sep.-Oct. 1994, vol. 7, No. 5, pp. 465-471, XP000590864.
Xie, et al, "Perfluoropropane Enhanced Sonicated Dextrose Albumin Produces Visually Apparent Consistent Myocardial Opacification With Physiologic Washout and Minimal Hemodynamic Changes Following Venous Injection", Apstract No. 362, 67th Scientific Sessions of the American Heart Association, Dallas, TX, USA, Nov. 14-17, 1994. In: Circulation, 1994, vol. 90, No. 4 Part 2, p. 269, XP000577055.
Porter, et al, "Visually Discernible Myocardial Echocardiographic Contrast After Intravenous Injection of Sonicated Dextrose Albumin Microbubbles Containing High Molecular Weight, Less Soluble Gases", abstract, J Am Coll Cardiol, Feb. 1995, vol. 25, No. 2, pp. 509-515, XP000590866.
Porter, et al, Noninvasive Identification of Acute Myocardial Ischemia and Reperfusion With Contrast Ultrasound Using Intravenous Perfluoropropane-Exposed Sonicated Dextrose Albumin, abstract, J Am Coll Cardiol, Jul. 1995, vol. 26, No. 1, pp. 33-40, XP000590865.
Porter, "The Mechanism and Clinical Implication of Improved Left Ventricular Videointensity Following Intravenous Injection of Multi-Fold Dilutions of Albumin With Dextrose", Int. J. Card Imaging, Jun. 1995, vol. 11, No. 2, pp. 117-125, XP000590839.
Xie F. et al., "Acute Myocardial Ischemia and Reperfusion Can be Visually Identified Non-Invasively with Intravenous Perfluoropropane-Enhanced Sonicated Dextrose Albumin Ultrasound Contrast", Abstract No. 2989, 67th Scientific Sessions of the American Heart Assoc., Dallas, TX, USA, Nov. 14-17, 1994. Circulation, 1994, vol. 90, No. 4 part 2, p. 1555, XP000577054.
Porter, et al., "Echocardiographic Detection of Residual Coronary Flow Abnormalities and Stenosis Severity After Coronary Reperfusion Using Intravenous Perfluoropropane-Enhanced Sonicated Dextrose Albumin", Abstract No. 955-60, 44th Annual Scientific Session of the American College of Cardiology, New Orleans, LA, USA, Mar. 19-22, 1995. In: Journal of the American College of Cardiology, Spec. Issue, p. 205A., XP000577058.
Putterman, S, Feb. 1995, Sonoluminescence: Sound Into Light, Scientific American, pp. 46-51.
Porter, Thomas R., "Myocardial Contrast Echocardiography for the Assessment of Coronary Blood Flow Reserve: Validation in Humans", JACC, vol. 21, No. 2, Feb. 93:349-55.
Bleeker, Hendrik, "On the Application of Ultrasonic Contrast Agents for Blood Flowmetry and Assessment of Cardiac Perfusion", J Ultrasound Med 9:461-471, 1990.
Hollinden Gary E.
The Board of Regents of the University of Nebraska
LandOfFree
Perfluorocarbon ultrasound contrast agent comprising microbubble does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Perfluorocarbon ultrasound contrast agent comprising microbubble, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Perfluorocarbon ultrasound contrast agent comprising microbubble will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1605314